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Themodern era of drug development for Alzheimer’s
disease began with the proposal of the cholinergic
hypothesis of memory impairment and the 1984
research criteria forAlzheimer’s disease. Since then,
despite the evaluation of numerous potential treat-
ments in clinical trials, only four cholinesterase
inhibitors and memantine have shown sufficient
safety and efficacy to allowmarketing approval at an
international level. Although this is probably
because the other drugs tested were ineffective,
inadequate clinical development methods have also
been blamed for the failures. Here, we review the
development of treatments for Alzheimer’s disease
during the past 30 years, considering the drugs,
potential targets, late-stage clinical trials, develop-
ment methods, emerging use of biomarkers and
evolution of regulatory considerations in order to
summarize advances and anticipate future devel-
opments.Wehave considered late-stageAlzheimer’s
disease drug development from 1984 to 2013,
including individual clinical trials, systematic and
qualitative reviews, meta-analyses, methods, com-
mentaries, position papers and guidelines. We then
review the evolution of drugs in late clinical devel-
opment, methods, biomarkers and regulatory
issues. Although a range of small molecules and
biological products against many targets have been
investigated in clinical trials, the predominant drug
targets have been the cholinergic system and the
amyloid cascade. Trial methods have evolved incre-
mentally: inclusion criteria have largely remained
focused on mild-to-moderate Alzheimer’s disease
criteria, recently extending to early or prodromal
Alzheimer disease or ‘mild cognitive impairment due
to Alzheimer’s disease’, for drugs considered to be
disease modifying. The duration of trials has
remained at 6–12 months for drugs intended to
improve symptoms; 18- to 24-month trials have
been established for drugs expected to attenuate
clinical course. Cognitive performance, activities of
daily living, global change and severity ratings have
persisted as the primary clinically relevant out-
comes. Regulatory guidance and oversight have
evolved to allow for enrichment of early-stage
Alzheimer’s disease trial samples using biomarkers
and phase-specific outcomes. In conclusion, vali-
dated drug targets for Alzheimer’s disease remain to
be developed. Only drugs that affect an aspect of
cholinergic function have shown consistent, but
modest, clinical effects in late-phase trials. There is
opportunity for substantial improvements in drug
discovery and clinical development methods.
Keywords: Alzheimer, clinical trial, dementia, drug
development, treatment.
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Introduction
The 9th Key Symposium marks an opportunity to
examine the 30-year history of drug development
and clinical trials for Alzheimer’s disease. In this
review, we will examine and assess recent thera-
peutic endeavours to understand the evolution of
the drug development paradigms and anticipate
future directions. Discovery and clinical develop-
ment of Alzheimer’s disease treatments have been
propelled by an enormous clinical need and a
potentially huge world market. Consequently, drug
development in this area has become a major
political, academic and industrial effort. Despite
considerable advances in knowledge of the patho-
genesis of Alzheimer’s disease and in medicinal
chemistry, no practical treatments have been
introduced over the past quarter of a century.
Only four cholinesterase inhibitors and memantine
have been marketed for the treatment of Alzhei-
mer’s disease and none since 2002 in Europe and
2003 in the USA. Two reviews in 2008 identified
over 100 [1] and 172 [2] drug development failures
in the field of Alzheimer’s disease. The Pharma-
ceutical Research and Manufacturers of America,
PhRMA, an industry trade group, identified 101
failures and three successes since 1998 [3]. Drug
discovery in neuroscience in general is compli-
cated, lengthy and uncertain, with an overall
failure rate greater than 95%. Any given develop-
ment programme may continue for 10–15 years
from discovery to marketing approval [3].
The modern era of clinical trials for Alzheimer’s
disease began with the advent of the cholinesterase
inhibitors as a cognitive therapeutic during the late
1970s and early 1980s [4, 5]. This early work led to
a proposed multicentre trial of orally administered
physostigmine to be funded by the US National
Institute on Aging (NIA). This proposal led to a trial
of the cholinesterase inhibitor tacrine after the
latter caused controversy and came to the attention
of US politicians [6]. A two-stage design trial
involving an initial crossover dose-finding phase,
followed by a 6-week parallel group, was funded by
both the NIA and Warner Lambert Pharmaceuticals
[7]. Other cholinesterase inhibitors under develop-
ment at the time, including velnacrine and a
sustained-release formulation of physostigmine,
employed a similar paradigm [8, 9].
These trials used a simple, seven-point clinician’s
global impression of change (CGIC) [10] and the
Alzheimer’s Disease Assessment Scale – cognitive
subscale (ADAS-cog) [11] as end-points. Trial
methods were facilitated in 1984 by the advent of
the National Institute of Neurological and Commu-
nicative Disorders and Stroke–Alzheimer’s
Disease and Related Disorders Association (NIN-
CDS-ADRDA) consensus criteria for Alzheimer’s
disease, known as the McKhann et al. criteria [12]
that were soon incorporated into the 3rd revised
edition of the American Psychiatric Association
Diagnostic and Statistical Manual of Mental Disor-
ders (DSM-III-R) [13].
US Food and Drug Administration (FDA) advisory
committees in 1989, 1991 and 1993 that discussed
trial methods, as well as a new drug application for
tacrine and unofficial unpublished FDA guidelines
in 1990 [14], helped to further shape the process
under which a drug could be approved for treat-
ment of Alzheimer’s disease. In 1993, the cholines-
terase inhibitor tacrine, branded Cognex (Pfizer,
New York, NY, USA), was the first drug approved ‘for
the treatment of mild to moderate dementia of the
Alzheimer’s type’.
Methods
We selectively reviewed late-stage drug develop-
ment and trials for Alzheimer’s disease from 1984
to 2013, including individual clinical trials, sys-
tematic and qualitative reviews, meta-analyses,
methods, commentaries, position papers and
guidelines. We focused on the methods, trends
and results of phase 2 and 3 trials with the goal of
summarizing advances and anticipating future
developments. Finally, we considered the evolution
of drugs in late-stage clinical development, along
with methodology, use of biomarkers, the contri-
butions of regulators and future directions.
Historical review of drug development and trials
In 1974, Drachman and Leavitt suggested that
memory was related to the cholinergic system
and was age dependent [15], a notion that is still
considered valid today. Around the same time
two British groups independently demonstrated
that the pathology of Alzheimer’s disease was
associated with a severe loss of central choliner-
gic neurons; more precisely, the severity of
dementia was correlated with the extent of cho-
linergic loss in the nucleus basalis of Meynert
[16, 17]. Alzheimer’s disease was conceptualized
as a cholinergic disease, similar to the way that
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Parkinson’s disease is considered a dopaminergic
disease [18].
The cholinergic hypothesis drove drug develop-
ment and trials throughout the 1980s and 1990s.
It continues to provide a basis for current develop-
ment efforts with neuronal nicotinic receptor mod-
ulators and other small molecules that have effects
on cholinergic function, including muscarinic and
nicotinic agonists, partial agonists and allosteric
modulators, and 5-hydroxytryptamine (5-HT)
receptor subtype-specific molecules [4] (Table 2).
Although other themes for therapeutic agents (e.g.
neuroprotective, anti-inflammatory and nutri-
tional/metabolic interventions) and targets for
Alzheimer’s disease emerged in the early 1990s,
drug development has been most influenced by the
cholinergic hypothesis and the amyloid cascade
hypothesis (see below).
The amyloid cascade hypothesis
The amyloid cascade hypothesis has become the
most-researched conceptual framework for Alzhei-
mer’s disease since its proposal in 1991 [19]. It has
been the dominant influence on the development of
targets and therapeutic agents for Alzheimer’s dis-
ease [20, 21]. The essence of the hypothesis is that
amyloid-b peptide (Ab) deposition is an early path-
ological process that drives tau phosphorylation,
neurofibrillary tangle formation and neuron death;
and that both the pathology and clinical expression
of Alzheimer’s disease result from the increased
production or impaired clearance of particular toxic
Ab species, particularly oligomers, produced by
sequential b- and c-secretase cleavage of the trans-
membrane protein amyloid precursor protein (APP).
This has led to the development of drugs to disrupt
the cascade and to clinical trials from the late 1990s
onwards to test them. Although simple in concept,
the validation and development of amyloid drug
targets has been complex in practice. For example,
oligomers, protofibrils and amyloid plaques may
have distinct toxicities. Oligomers may be toxic at
synapses, and plaque-associated Ab fibrils may be
pro-inflammatory and neurotoxic in their local (in-
terstitial) environment, thus constituting separate
drug targets. Despite extraordinary, extensive pre-
clinical researchandsubstantial clinical research, a
validated drug target has not been developed for
Alzheimer’s disease based on the amyloid cascade.
Specifically, it is not at all clear that inhibition or
modulation of APP secretases, inhibition of Ab fibril
aggregation or the use of antibodies targeting vari-
ous Ab forms are valid strategies. The first late-stage
trials specifically with ‘anti-amyloid’ drugs were not
conducted until 2001; notably these trials investi-
gated the use of an aggregated human Ab vaccine
with a conjugate (AN1792) [22].
Early symptomatic trials (approximately 1986–1996)
Despite initial dose titration, dose-ranging and
crossover studies designed to find the ideal individ-
ualizeddoses for cholinesterase inhibitors, thebasis
for regulatory approval of the cholinesterase inhib-
itors (and subsequently for memantine), were the
requirement of a minimum of one 3-month and one
6-month parallel group, randomized placebo-
controlled trials showing safety and effectiveness.
The regulatory authorities initially permitted two
3-month trials, but this was extended to a 6-month
trial after an FDA advisory committee in 1989 sug-
gested that6 monthswas theminimumtimeneeded
to demonstrate a clinicallymeaningful effect [23].
Full and partial agonists at the M1 muscarinic
receptor were also under development using sim-
ilarly designed 3-month and 6-month trials of
drugs including cevimeline (AF102B), milameline,
sabcomeline (SB 202026), talsaclidine, xanomeline
and alvameline (LU 25–109) [24]. Muscarinic ag-
onists in phase 2 and 3 studies generally showed
measurable efficacy in terms of cognition but with
considerable, acute parasympathetically mediated
adverse effects, including gastrointestinal symp-
toms, salivation, sweating and frequent urination.
These adverse effects, which overwhelmed poten-
tial clinical utility, may have been due to insuffi-
cient selectivity of the drugs explored for the M1
receptor subtype [24].
The most important drugs investigated in 3-month
and 6-month clinical development programmes
during this period were the cholinesterase inhibi-
tors including tacrine [7, 25, 26], velnacrine [8],
sustained-release physostigmine [9, 27], eptastig-
mine [28, 29], metrifonate [30], donepezil [31],
rivastigmine [32] and galantamine [33]. These
drugs were sometimes combined with the acetyl-
choline precursor lecithin in an effort to enhance
clinical effects [34, 35]. In addition, during this
period, several noncholinergic drugs were tested
that did not show efficacy in 6-month clinical trials,
including ergoloid mesylates (Hydergine) [36],
D-cycloserine [37] and selegiline [38].
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Six-month trials (approximately 1990–2001)
Development programmes were based almost
exclusively on the original tacrine programme,
and most subsequent cholinesterase inhibitors
that were advanced to phase 2b or 3 trials showed
cognitive efficacy in both 3- and 6-month trials in
patients with mild-to-moderate Alzheimer’s dis-
ease. Three cholinesterase inhibitors in addition
to tacrine were marketed in the USA: donepezil in
1996 (1997 in the UK), rivastigmine in 2000 (1998
in Europe) and galantamine in 2001 (2000). Other
cholinesterase inhibitors such as velnacrine, phy-
sostigmine, eptastigmine and metrifonate showed
efficacy as well, but were not marketed because of
adverse events, safety and patent issues.
The general efficacy of the marketed cholinesterase
inhibitors was considered modest with effects of
about 2–3 points on the standard cognitive out-
come, the ADAS-cog, and similarly small effects on
global assessments and activities of daily living
(ADL) over the course of 6 months [39]. The cogni-
tive effects of the three currently marketed cholin-
esterase inhibitors are depicted in Fig. 1.
Although the effects of cholinesterase inhibitors in
6-month trials were statistically robust, the small
size of the effects can be appreciated by consider-
ing that patients’ baseline scores on the ADAS-cog
are about 22–24 and so the effect represents about
a 10–12% improvement. Health economists and
systematic reviewers nevertheless recognized that
‘donepezil, rivastigmine and galantamine can delay
cognitive impairment’ based on the results of the
6-month trials [40, 41]. However, as branded
medications in the early 2000s, they were not
considered cost-effective for mild-to-moderate
Alzheimer’s disease by some health economists
[40, 41]. The fact that donepezil and other cholin-
esterase inhibitors are now available as generics
has substantially mitigated the economic issues of
their use.
Development programmes for dozens of other
drugs have been initiated based on the cholines-
terase inhibitor protocol of 6-month pivotal trials
[2, 5]. Nearly all failed on the basis of insufficient
cognitive efficacy. Some may have demonstrated
detectable cognitive effects, such as the muscarinic
agonists discussed above [24], but the effects were
slight, not supported by other clinical ratings or
not validated by further confirmatory trials.
The N-methyl-D-aspartate (NMDA) receptor antag-
onist memantine followed this development pattern
for both mild-to-moderate and moderate-to-severe
Alzheimer’sdisease.Efficacy in twoof three6-month
trials was observed for moderate-to-severe Alzhei-
mer’s disease and the drug subsequently received
Review: Cholinesterase inhibitors for Alzheimer’s disease
Comparison: 1 Cholinesterase inhibitor (optimum dose) vs placebo
Outcome: 1 ADAS-Cog mean changes in score from baseline at 6 months or later (ITT-LOCF)
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Fig. 1 Forestplots for 6-month trials of the three currently marketed cholinesterase inhibitors showing the general
consistency of effect, mean drug–placebo differences on the ADAS-cog and 95% confidence intervals. The overall mean effect
is 2.37 ADAS-cog points. Reproduced with permission from Birks [39].
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marketing approval in 2002 in Europe and in 2003
in theUSA.Memantinewasnot shown to be effective
in three, mild-to-moderate Alzheimer’s disease tri-
als and is not approved for mild Alzheimer’s disease
in Europe or the USA [42].
Twelve-month trials (approximately 1994–2010)
One possibility that may explain why the 6-month
trials were successful for drugs such as the
cholinesterase inhibitors is that they had clear
positive effects showing improvement in cognition
over the short term compared with baseline; in
addition, the combination of this slight positive
effect for the drug and a slight worsening for the
placebo group was sufficient to detect a statisti-
cally significant change. However, a large number
of drugs entered clinical development for which
absolute cognitive improvement was not expected,
but attenuation or halting of cognitive decline was
the expected therapeutic effect.
These drugs included those that might act as anti-
inflammatory and neuroprotective agents and met-
abolic enhancers. Trials in mild-to-moderate Alz-
heimer’s disease were extended to 12 months of
follow-up in order to be able to detect a stabiliza-
tion effect compared with the continuing decline for
the placebo group. These phase 2 and 3 trials
assessed prednisone [43], conjugated oestrogens
[44], transdermal selegiline [45] rofecoxib [46],
naproxen [47], celecoxib [48], acetyl-L-carnitine
[49, 50], ginkgo biloba extract [51], idebenone
[52], nicergoline [53] and propentofylline [54]. The
first phase 2 trials of an Ab vaccine, AN1792 [22],
and the first of a c-secretase modulator or Ab42-
lowering agent, tarenflurbil [55], were 12-month
trials. More recently phase 2 and pivotal 12-month
trials were conducted with drugs in development
for the treatment of Alzheimer’s disease, including
the growth hormone secretagogue MK-677 [56],
latrepirdine [57, 58] and the neuroprotective agent
T-817 [59].
Compared with the 6-month trials in mild-to-
moderate Alzheimer’s disease, those with a 12-
month duration reliably showed progression of
cognitive impairment in the placebo group. The
fact that cholinesterase inhibitors were marketed
based on 6-month trials provided little incentive for
their evaluation in longer studies. The one excep-
tion was a 12-month trial of donepezil that,
although showing drug–placebo differences on the
Mini-Mental State Examination (MMSE) [60]
favouring donepezil, illustrated that patients no
longer showed cognitive improvement after
12 months, continued to decline on other rating
scales and had high discontinuation or noncom-
pliance rates of about one-third over the
12 months [61].
One adaptation to the 12-month trial design was
the random allocation of patients with more mod-
erate impairment and their follow-up to a prede-
termined level of clinical or functional decline as
the study end-point, exemplified by a trial of
donepezil [62]. An earlier example was a 2-year
trial of selegiline and vitamin E intended to delay
loss of functional activities, nursing home place-
ment or death [63].
In summary, the 12-month trials were successful
in that their methods clearly demonstrated that the
various test drugs with the exception of donepezil
did not alter the decline in cognition that is reliably
observed with placebo treatment. These methods
continue to be used in late-phase drug develop-
ment.
Mild cognitive impairment trials (approximately 2000–2005)
The interest in treating early Alzheimer’s disease
evolved from consideration that a risk state can be
identified before the onset of the dementia syn-
drome. The concept of incipient cognitive impair-
ment as detected by the mild cognitive decline
stage of the Global Deterioration Scale [64], the
‘questionable dementia’ or the 0.5 stage of the
Clinical Dementia Rating scale (CDR) [65], was
established in the 1980s. This stage may repre-
sents very early Alzheimer’s disease before the
onset of dementia, that is, not fulfilling the McKh-
ann et al. criteria.
Subsequently, mild cognitive impairment (MCI)
and amnestic MCI were characterized in the late
1990s as progressive memory impairment similar
to that seen in patients with early Alzheimer’s
disease but with less impairment in other cognitive
and functional domains. Such individuals were
shown to decline at a greater rate than nonim-
paired control subjects, such that about half
developed Alzheimer’s disease (dementia) within
3 years [66]. The idea that amnestic MCI could be a
clinical target for early treatment interventions was
facilitated by an FDA advisory committee in 2001
[67] that coincided with some longer-term clini-
cal trials of MCI. These trials used continuous
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treatment over 2–4 years with the main outcome of
progression to Alzheimer’s disease dementia and
secondary outcomes of change in cognitive rating
scales. The drugs investigated included the mar-
keted agents rivastigmine, galantamine, donepezil,
vitamin E, vitamin B complex and rofecoxib
[68–72]. The nootropic piracetam was used in a
small 1-year MCI pilot trial [73] and donepezil in
larger 6- [74] and 12-month trials [75].
The results of all the trials in MCI were negative,
with no significant benefit on progression or onset
of Alzheimer’s disease dementia. The rates of
progression from MCI to Alzheimer’s disease
tended to be lower than expected based on prior
cohort studies of MCI [66]. The different rates of
progression could have been due to variations in
sample ascertainment, heterogeneity of patients
and different definitions of MCI and of outcomes.
Of particular importance to drug development, the
trial assessing the anti-inflammatory rofecoxib
showed significant cognitive-impairing effects
compared with placebo, but these effects were
explainable, post hoc, by the fact that nonsteroidal
anti-inflammatory drugs (NSAIDs) are associated
with cognitive impairment and delirium and that
smaller phase 2 trials had not been performed to
demonstrate proof of concept or assess safety.
Rofecoxib was later withdrawn from the market
because of cardiotoxic events, but at the time the
MCI trial was conducted, the sponsors presumably
did not think that phase 2 proof of concept or safety
studies were necessary. Yet the planning and
execution of the trial foreshadowed a current trend
in drug development for Alzheimer’s disease to
bypass phase 2 studies on the basis that phase 3
would better demonstrate efficacy and safety.
Individual MCI trials are reviewed, contrasted and
compared elsewhere [73, 76]. Figure 2 summarizes
the cognitive and functional outcomes from these
trials, showing also the broad heterogeneity of
outcomes.
Regulatory considerations for trials of MCI
In 2001 an FDA advisory committee clarified drug
development for Alzheimer’s disease by suggesting
several requirements for the marketing approval of
drugs for MCI [67]: (i) MCI must be clearly defined
in the clinical setting, (ii) there are valid criteria for
its diagnosis, (iii) it is either distinguished from or
defined in terms of future onset of Alzheimer’s
disease, (iv) appropriate outcomes are used in
trials, and (v) trials should be designed to assess
rating scale changes, onset of dementia and clin-
ically meaningful effects.
Post hoc analyses of these trials variously suggested
that one subgroup or another had potentially ben-
efited fromcholinesterase inhibitor treatment.How-
ever, as post hoc analyses, these findings did not
gain acceptance and confirmatory trials were not
conducted to test the hypotheses. The failures of
MCI trials led to the consideration at the time that
MCI was a heterogeneous at-risk state that did not
necessarily lead to Alzheimer’s disease; indeed, it
might be too early in the disease course for the then
current drugs to be effective. The European Medi-
cinesAgency (EMA) clearly stated thatMCI couldnot
be recognized as a clinical entity for which target
drugs could be developed, and more work on char-
acterization of diagnostic criteria including the role
of aetiological subtypes and the development of
appropriate assessment tools had to be done [77].
Moreover, the fact that a marketing claim could not
be achieved for delaying onset of Alzheimer’s disease
or disease modification, but rather only for the
existing claim, ‘for the treatment of Alzheimer’s
disease’, probably contributed to the lackof interest.
Thus, there was little commercial incentive to pur-
sue MCI as a clinical target.
Eighteen-month and disease-modifying trials (approximately 2001–
2013)
Limited experience with 12-month trials led to the
notion that longer trials could be helpful in show-
ing sufficient progression in the placebo group so
that the effect of a drug that only attenuated
decline (or lost its positive effect early) could be
better detected. It was also reasoned that the
temporal resolution of the ADAS-cog should be
better at 18 months than at 12 months, although
this may not be the case [78]. These longer trials
represented a departure from testing drugs that
improved function to a model in which attenuation
of decline was the desired outcome.
As with the 12-month trials, anti-inflammatory
and neuroprotective agents were initially tested in
18-month trials of hydroychloroquine [79], the
cholesterol-reducing 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitors
atorvastatin [80] and simvastatin [81], food sup-
plements such as vitamin B combinations to lower
homocysteine [82] and docosahexaenoic acid [83].
Except for two very large phase 3 trials with the
neuroprotective 5-HT1A agonist xaliproden [84],
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the early 18-month trials investigated marketed
drugs or available food supplements. More recent
phase 2 and 3 trials involved almost entirely
investigational drugs to test the amyloid hypothe-
sis. These included an Ab aggregation inhibitor
tramiprosate [85], two phase 3 trials of a gamma-
secretase modulator to lower Ab levels, tarenflurbil
[86], the Ab aggregation inhibitor scyllo-inositol
(ELND005) [87], two trials of the gamma-secretase
inhibitors semagacestat [88]and one of avagace-
stat [89], a RAGE inhibitor (PF 04494700 or TTP
488), infusions of Ab antibodies including phase 2
and 3 trials of bapineuzumab [90] [unpublished],
two phase 3 trials of solanezumab [unpublished]
and immunoglobulin G (IVIG) [unpublished]. All
these trials yielded null results with respect to
their main outcomes. Other 18-month trials are
ongoing.
The 18-month trials have been similar in design to
earlier trials, using the same inclusion criteria and
outcomes, except that usually cholinesterase
inhibitors and memantine have been allowed as
concomitant medications. In fact, 80–90% of par-
ticipants in later trials have been maintained on
these drugs. Although most included mild-to-mod-
erate Alzheimer’s disease (allowing a maximum
MMSE score of 26), the lower limit defining ‘mod-
erate’ severity has varied from a score of 12–20
such that some trials focused exclusively on ‘mild’
Fig. 2 Outcomes of clinical trials of cholinesterase inhibitors for mild cognitive impairment showing a general lack of
cognitive and global effects in trials from 2 to 4 years in duration (except for one 24-week trial). The data show the point
estimates and 95% confidence intervals of the drug–placebo differences. The Z-cognitive is a composite of the
neuropsychological test battery used in the rivastigmine trial. Reproduced with permission from Raschetti et al. [76].
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Alzheimer’s disease (i.e. restricting the MMSE score
to 20–26). Patient groups in these trials are com-
parable to groups in the 6-, 12- and 18-month
trials with respect to age, gender, apolipoprotein E
(APOE) genotype distribution, education and clin-
ical rating scale scores [78].
Recent enhancements to 18-month trial designs
have been the addition of cerebrospinal fluid (CSF)
and brain imaging measures of amyloid deposition,
CSF assays of tau concentration and volumetric
magnetic resonance imaging (MRI) to detect neu-
rodegeneration. These biomarkers were first used
in subsets of patients in the hope that any clinical
effects could be better explained or that a change in
a marker during a trial would be considered as
supportive evidence of a disease-modifying effect.
More recently, and perhaps influenced by EMA
guidelines on sample enrichment with biomarkers
[91, 92], these biomarkers have been used to help
‘enrich’ or restrict clinical trial samples to patients
with evidence of amyloid pathology. The rationale
is that biomarker enrichment will more accurately
identify trial participants with Alzheimer’s disease
pathology and perhaps select those more likely to
respond to the investigational drug, although this
is without empirical support [91].
The design of these longer trials has been influ-
enced by expert group recommendations that the
most well-established scales be used, that is, the
ADAS-cog, Alzheimer’s Disease Cooperative Study–
Activities of Daily Living (ADCS-ADL) scale and
CDR, because of a lack of suitable alternatives; in
addition, a 2-point drug–placebo group difference
on the ADAS-cog would be the minimal mean
change required to denote a clinically meaningful
effect [93, 94]. Notably, this change is less than
that observed with cholinesterase inhibitors and
less than the 4-point difference recommended by
an FDA advisory committee in 1989 [23].
For an 18-month trial to better detect efficacy using
the clinical outcomes above, the placebo group
must decline to a substantial extent, whilst the drug
group still needs to improve slightly over baseline to
offset the large variances in the change in rating
scales. Initial sample sizes need to be large enough
to gain this precision and counter the effects of large
numbers of dropouts. Indeed, the sample sizes of
18-month trials have increased from about 400–
1200 patients for industry-sponsored phase 3 trials
in mild-to-moderate Alzheimer’s disease, and to
2100 for a trial limited to participants with mild
Alzheimer’s disease treated with the Ab antibody
solanezumab (http://www.clinicaltrials.gov/ct2/
show/NCT01900665?term= LZAX&rank=1). This
trial should be able to detect less than a 1.5- and 2-
point drug–placebo difference on the 11-item and
14-item ADAS-cog, respectively.
Although most ADL scales may not be accurate or
able to assess the ‘functional domain’ in a clinically
meaningful way, they are considered relevant for
helping to determine disease modification and are
consistent with patients’, caregivers’ and health
economists’ perspectives with regard to effective
treatment. In view of this, even an effect as small as
a 1.5-point change on the ADCS-iADL over
18 months might be considered sufficient in early
Alzheimer’s disease.
Many characteristics of these trials, such as the
modest decline of placebo group rating scores,
heterogeneity and variability of clinical course,
imprecision of the outcomes and the expectation
that new drugs will only attenuate decline, when
taken together, diminish the likelihood of discov-
ering modestly effective drugs using these trial
designs. Therefore, as above, biomarker enhance-
ment, large sample sizes and more diligent training
of clinical raters are expected to provide greater
efficiency.
In summary, 18-month, placebo-controlled trials
have become a de facto standard for trials of mild
and moderate Alzheimer’s disease even though no
18-month trial has shown statistically significant
primary outcomes favouring the test drug in a
priori analyses. The use of biomarkers such as CSF
Ab and tau, volumetric MRI and amyloid positron
emission tomography (PET) may allow demonstra-
tion of disease modification, depending on the
mechanism of action of the drug.
Prodromal Alzheimer’s disease trials (approximately 2010–2014)
The earlier MCI trials used slightly differing defi-
nitions for MCI, including amnestic MCI in one
trial [68] which later became ‘MCI due to Alzhei-
mer’s disease’ for the Alzheimer Disease Neuroi-
maging Initiative and for the new research
diagnostic guidelines for Alzheimer’s disease in
2011 [95]. The advancement of trials for prodro-
mal Alzheimer’s disease followed proposed
research criteria from an international workgroup
[96], that is, with the intent to diagnose Alzheimer’s
disease before dementia onset and to enrich clinical
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trial samples in terms of increasing confidence that
patients actually had Alzheimer’s disease pathology
and presumably would advance to dementia after a
relatively brief interval [97]. The inclusion of
patients with prodromal disease also allows indi-
viduals to be treated earlier in their illness and,
hypothetically, at a time when some drugs may be
more effective than they would be at a later stage.
The current ‘MCI due to Alzheimer’s disease’ and
prodromal Alzheimer’s disease trials have charac-
teristics similar to the 18-month trials described
above and include a requirement that participants
have positive Ab biomarkers, such as low CSF Ab42
concentrations or increased retention of an Ab-
binding ligand on amyloid PET scan, to enhance
the likelihood that participants have Alzheimer’s
disease pathology. These trials are different from
previous MCI trials in having somewhat shorter
treatment periods of 18–24 months and in the use
of biomarkers both for entry criteria and as indices
of change that might be interpreted as supportive
of disease modification. A number of these trials
are listed in Table 1.
As an example, a phase 2/3 trial in patients with
prodromal Alzheimer’s disease uses a cognitive test
threshold requirement followed by an amyloid
biomarker requirement to define prodromal Alzhei-
mer’s disease. In this trial, the Ab antibody gan-
tenerumab or placebo are given intravenously over
a 2-year period. Anticipating the FDA draft guide-
lines for early-stage Alzheimer’s disease [98], the
CDR-sum of boxes (CDR-SB) is used as the sole
primary outcome, supported by cognitive, func-
tional and biomarker secondary outcomes. As with
earlier trials, if the primary outcome is not statis-
tically robust and supported by most secondary
outcomes, interpretation of the drug’s clinical
meaning will be challenging.
Prevention trials (approximately 1996–2014)
Prevention trials are logical extensions of MCI and
prodromal trials and address the fact that the
pathology of Alzheimer’s disease is progressing
perhaps two decades before the onset of dementia
[99]. The shift towards recognizing presymptomatic
and preclinical phases of Alzheimer’s disease,
before the prodromal or MCI stage [97], has
furthered the need for prevention treatment trials.
There have been only a handful of completed
prevention trials, in large part because they require
large samples, prolonged follow-up, are complicated
and expensive to conduct, and until recently were
hindered by the lack of compelling and safe drugs or
interventions to test [100]. Known and presumed
risk and protective factors for Alzheimer disease
strongly influence the design and prosecution of
these trials despite the fact that Alzheimer dementia
and Alzheimer neuropathology do not necessarily
involve the same risk factors [101]. Prevention trials
have tended to select participants with risk factors
such as family history, cardiovascular disease,
relatively greater age or existing MCI in an effort to
increase the numbers of individualswhoprogress to
dementia over a typical 5-year follow-up.
Dementia prevention trials have generally used
available, marketed or safe drugs and food sup-
plements, and often as an add-on or nested within
a larger trial for another condition, such as the
preventive effects of antihypertension medications,
conjugated oestrogens, an HMG-CoA reductase
inhibitor or vitamin E and selenium [102]. There
have been two prevention trials using Ginkgo
biloba standardized extract EGb 761 [103, 104],
and one using two NSAIDs [105]. These as well as
prevention trials of antihypertensive agents [106]
did not show protective effects on cognitive func-
tion or dementia onset and, indeed, in some cases
may have shown the opposite [100].
Recent advances in prevention trials include
enrolling elderly people with an increased risk of
Alzheimer’s disease based on a biomarker or
genetic marker, and the use of multidomain inter-
ventions composed of concurrent management of
risk factors based on lifestyle changes and mar-
keted pharmacological products. The trials include
the Finnish Geriatric Intervention Study to Prevent
Cognitive impairment and Disability (FINGER),
Multi-domain Alzheimer Prevention Study (MAPT)
and Prevention of Dementia by Intensive Vascular
Care (PreDIVA) [107]. Additionally, there are a
number of planned trials involving structured
physical activity interventions that are discussed
elsewhere in this issue [107].
The current, single-drug, pharmaceutical com-
pany-sponsored prevention trials are components
of proprietary drug development programmes in
which participants must have an Ab biomarker as
an enrichment or risk factor, or a genetic risk
marker or specific PSEN 1 or APP mutation that
determines their eligibility. These studies include
the Alzheimer’s Prevention Initiative (API), the
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Dominantly Inherited Alzheimer Network (DIAN),
the Anti-amyloid Treatment in Asymptomatic Alz-
heimer’s Disease (A4) and the ApoE/TOMM40
trials; the first three tested Ab antibodies and the
latter a very low dose of the thiazolidinedione
pioglitazone [107].
The two trials in patients with autosomal domi-
nantly inherited Alzheimer’s disease are unique in
that there is no question that all participants will
develop cognitive and neurological impairment and
will have Alzheimer’s disease pathology. As partic-
ipants are symptom free, they can be considered to
have preclinical Alzheimer’s disease. Both trials are
investigating the efficacy of Ab antibodies – cre-
nezumab in the API and gantenerumab and sola-
nezumab in the DIAN study – and so are also tests
of the amyloid hypothesis. One consideration is
that Aß42-reducing approaches may have a par-
ticular effect in familial Alzheimer’s disease where
Aß42 formation is increased, compared with spo-
radic Alzheimer’s disease where Aß42 formation is
not affected. The A4 trial is testing the concept of
treating participants who are amyloid PET positive,
without notable cognitive symptoms (i.e. who are at
statistical risk of sporadic, late-onset Alzheimer’s
disease), with the Ab antibody solanezumab.
The pioglitazone trial is also unique in that it
includes approximately 5000 noncognitively
impaired participants whose increased risk of
Alzheimer’s disease is determined by a biomarker
comprising age, particular variants of the TOMM40
gene and APOE genotypes; the efficacy of low-dose
pioglitazone to delay the onset of MCI due to
Alzheimer’s disease will be evaluated over the
course of 6 years in the high-risk biomarker group.
In summary, prevention trials select participants
based on enhanced risk of Alzheimer’s disease or
preclinical Alzheimer’s disease status, use mar-
keted medications, food supplements, environmen-
tal interventions, Ab antibodies or pioglitazone in
randomized, placebo-controlled trials with 3- to
6-year follow-up periods and both cognitive change
and time to onset of cognitive impairment or demen-
tia as end-points.
The evolution of pharmacological targets and the new symptomatic
phase (approximately 2007–2014)
The amyloid cascade hypothesis [19] has domi-
nated drug development for the past two decades.
Targets were developed for individual steps in the
cascade: secretase inhibitors and modulators, pas-
sive and active immunization with antibodies
against various epitopes of Ab monomers, oligo-
mers and fibrils, fibrilization inhibitors, anti-ag-
gregants and other approaches. As a result of
recent development failures, the currently active
phase 2 and 3 anti-amyloid approaches involve
three antibodies with an emphasis on mild, pro-
dromal and preclinical Alzheimer’s disease: Ab
vaccines, and beta-site amyloid precursor protein
cleaving enzyme 1 (BACE-1) and b-secretase inhib-
itors. There are several examples of vaccines in
development, including CAD-106, ACC-001, V950,
AC-24, AD01 and AD02, all composed of peptides
or fragments that mimic Ab42 (Table 3).
The BACE-1 competitive inhibitor MK-8931 is
being assessed in prodromal and mild-to-moderate
Alzheimer’s disease populations in two phase 2
trials for 2 years and 18 months, respectively, with
the latter enrolling over 1900 patients
(NCT01739348). Other BACE-1 inhibitors are in
development, although there have been failures
due to toxicity.
Interest in tau-based approaches has led to
putative inhibitors of enzymes involved in tau
phosphorylation (e.g. GSK-3b), aggregation inhib-
itors, microtubule stabilizers and inhibitors of tau
N-glcNAcylation. Agents in development include
small molecules, monoclonal antibodies and vac-
cines. Most advanced is a formulation of methylene
blue, methylthioninium chloride, (TRx0237)
(TauRx), that may act as a tau aggregation inhib-
itor. It showed uncertain outcomes in a 6-month
phase 2 trial but adequate safety [108] and is
currently being tested in two phase 3 trials, a
12-month trial in mild-to-moderate Alzheimer’s
disease with 833 patients and an 18-month trial
in mild Alzheimer’s disease with 500 patients. Anti-
tau approaches in clinical development are listed
in Table 3.
Despite the interest in amyloid-targeted drugs for
longer-term, disease-modification trials, there has
been continued interest in small molecules that
would have relatively quick and symptomatic
effects targeting a range of receptor complexes that
result in cholinergic enhancement, or modulate
monoamine and other neurotransmitter systems
(Table 2). Success was reported with these investi-
gational drugs in phase 2, 6-month trials using the
ADAS-cog as the primary clinical outcome, and in
particular with the 5-HT6 antagonist Lu AE58054
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Table 2 Alzheimer’s disease (AD) treatment: recent therapeutic approaches in phase 2 or 3. Mainly symptomatics, targeting
neurotransmission





improve cognition in mild–moderate
AD [39]; (>45 RCTs, >18 000 subjects,
mainly 6-month duration) [31–33]
MCI: no clinical effects, increased
adverse events [76]
Muscarinic receptor agonists Some compounds tested in phase 1
RCTs (e.g. talsaclidine, AF-102B,
AF267B) were discontinued due to
adverse effects due to peripheral
cholinergic stimulation [21, 24]
Nicotinic receptor agonists
(modulators of the nicotinic receptors




AZD-3480 (modulators of nicotinic
receptors a4b2, a2b2): no evidence of
benefit in a 3-month phase 2 RCT in
567 patients with mild–moderate AD
[130]
EVP-6124 (modulator a7 receptor):
positive results in a 24-week phase 2b
RCT in 409 cases of mild–moderate AD
[132]
MT-4666 (a7 modulator): 6 months,
phase 2 RCT in 450 patients with
mild–moderate AD
AZD-3480: phase 2 RCT in mild–
moderate AD (1 year,  300
participants)
ABT-126: two phase 2, mild–
moderate AD, 6 months 820
participants with and without stable
ChEI treatment
EVP-6124: two phase 3 trials in 1580
subjects with mild–moderate AD,
26 weeks.
MK-7622 (a7 modulator): phase 2b,






Memantine: clinical benefits in
moderate–severe AD, mainly 6 months
[133]. Not effective in mild AD [134]
DAOI-B (NMDA enhancer): 6 months,
phase 2 RCT in 86 subjects with MCI
or mild AD (not published)
AVP-923 (dextromethorphan/
quinidine): phase 2 RCTs in mild–
moderate AD (main outcome:
behavioural problems, 10 weeks, 
200 participants)
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(Lundbeck, Valby, Denmark) and the a7 nicotinic
modulators EVP6124 (En Vivo pharmaceuticals,
Brighton, MA, USA), ABT-126 (Abbvie, North Chi-
cago, IL, USA) and MK-7622 (Merck, Whitehouse
Station, NJ, USA). Thus, the pursuit of the cholin-
ergic hypothesis has continued, and cholinergic
pathways remain viable drug targets (Table 2) .
Monoamine oxidase (MAO)-B inhibitors are being
revisited since the early trials of selegiline [38] and
derivatives in the 1990s. One MAO-B inhibitor,
RO4602522 (EVT 302) (Roche, Basel, Switzer-
land), is being tested in a phase 2 dose-ranging
trial including 495 patients with moderate
Alzheimer’s disease, that is, MMSE from 13 to
20, treated for 12 months (NCT01677754)
(Table 2).
Some so-called symptomatic drugs are in develop-
ment to improve cognition in patients with cogni-
tive impairment associated with schizophrenia and
in those with attention deficit disorder. Examples
include phosphodiesterase-9 inhibitors and agents
to increase activation of the NO/cGMP pathway
(Table 4). For the latter class, preclinical evidence
suggests an effect similar to that of acetylcholines-
terase inhibitors, and clinical data are now being
collected in phase 2a trials. These drugs are being
developed in 6-month trials in mild-to-moderate
Alzheimer’s disease using the same framework as
for the cholinesterase inhibitors, but cholinester-
ase inhibitor treatment is allowed as background
therapy in some trials.
In summary, anti-amyloid and tau-based
approaches are being advanced in 18-month trials
in patients with mild and prodromal Alzheimer’s
disease,andsmallmolecule,cholinergicapproaches
are entering phase 3 in 6-month trials in patients
with mild-to-moderate dementia. The cholinergic
approachesarebettersupportedby ‘proofofconcept’
trials and appear to improve clinical outcomes.
Table 2 (Continued )
Main mechanism of action or class RCTs completed (examples) RCTs ongoing (examples)
Serotoninergic agents
5-HT6 receptor antagonists: effects on
cholinergic, glutamatergic and
monoaminergic neurons
SB742457: positive results in three
phase 2 RCTs, 6 months,  1460
patients with mild–moderate AD; 1
negative RCT [135]
Lu AE58054: positive outcomes in one
phase 2 RCT in mild–moderate AD,
6 months, 278 participants
(NCT01019421)
Lu AE58054: several phase 3 trials
with about 2500 patients with mild–






Selegiline and vitamin E for moderate
AD [61] Selegiline: meta-analysis of 17
RCTs including 1143 subjects with
moderate–severe AD, durations from 3
to 105 weeks, some positive effects,
but overall no significant clinically
meaningful benefits
RO4602522 (EVT 302): phase 2 RCT in
495 patients with moderate AD,
1 year
Multi-target-directed ligands
Ladostigil (TV-3326): derivative of
rasagiline and rivastigmine, acts as
an AChEI and MAO-I, antioxidant
properties, modulates APP processing
Phase 2 RCTs in MCI (3 years,  200
participants) and mild–moderate AD
(26 weeks + 26 weeks open label, 
188 participants)
RCT, randomized controlled trial; GABA, c-aminobutyric acid; NMDA, N-methyl-D-aspartate; AChEI, acetylcholinesterase
inhibitor, APP, amyloid precursor protein.
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Table 4 Alzheimer’s disease (AD) treatment: recent and current therapeutic approaches in phase 2 or 3. Other approaches
Main mechanism of action RCTs completed (examples) RCTs ongoing (examples)
Nutraceuticals and food supplements
Macro/micronutrients, alone and in
combination: antioxidants, omega-3-
PUFAs, vitamins B
PUFA: 6-month RCT in 174 subjects
with mild–moderate AD did not report
beneficial effect on cognition and CSF
markers of AD [154, 155]. 18-month,
phase 3 RCT in 285 participants with
mild–moderate AD showed absence of
benefits on cognition and functional
status [83]
PUFA: several RCTs in which PUFAs
are tested alone or combined with
other supplements (e.g. lipoic acid) or
lifestyle interventions. Subjects with
different levels of cognitive
impairment have been enrolled,
duration 6 months to 3 years
Phosphodiesterase inhibitors
Regulate cGMP signalling pathways
involved in synaptic plasticity and
inflammation
PF-04447943: selective PDE 9A
inhibitor tested in a phase 2 RCT in
200 subjects with mild–moderate AD
(completed 2009, not published)
MK0952: PDE4 inhibitor, phase 2
RCT in mild–moderate AD (completed,
results not published)
Cilostazol: PDE3 inhibitor, approved
for stroke prevention. Open trial in 10
patients with moderate AD: safety,
possible cognitive benefit [156]
Tyrosine kinase inhibitor Masitinib, phase 3, 6 months 400
participants with mild–moderate AD
(NCT01872598)
Cholesterol lowering
HMG-CoA reductase inhibitors have
multiple effects: ↓ Ab production, Ab-
mediated neurotoxicity, antioxidant,
anti-inflammatory
Simvastatin and atorvastatin: two
phase 3 RCTs,  1100 subjects,
showed no benefits in mild–moderate
AD after 18 months [78, 79]
Simvastatin: RCTs of effects on AD
biomarkers, 1 year,  120
participants; and preventing/
delaying progression to dementia in
aMCI, 2 years,  640 participants
Insulin and glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists
Improve insulin-mediated signalling,
brain glucose metabolism, neuro-
transmission, possible effects on Ab
neurotoxicity
Intranasal insulin: 4-month phase 2
RCT, 111 subjects with aMCI andmild
AD; some cognitive benefits reported
[157]
Intranasal insulin: Phase 2/3 in aMCI
and mild AD, 18 months,  240
participants
Exendin-4 (GLP-1R): phase 2 RCT in
230 subjects with MCI or early AD,
3 years
Liraglutide (GLP-1R): phase 2 RCT in
206 subjects with mild AD, 1 year
cGMP, cyclic guanosine monophosphate; CSF, cerebrospinal fluid; GSK-3, glycogen-synthase-kinase-3; PDE, phospho-
diesterase; PUFAs, polyunsaturated fatty acids; ARIA-E, amyloid-related imaging abnormalities with parenchymal
oedema; ARIA-H, amyloid-related imaging abnormalities with intracerebral microhaemorrhages. RCT: randomized
controlled trial; aMCI: amnestic mild cognitive impairment; HMG-CoA: 3-hydroxy-3-methyl-glutaryl-CoA reductase;
↓: reduction.
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Diagnoses for clinical trials in Alzheimer’s disease
The McKhann et al. [12] criteria for possible, prob-
able and definite Alzheimer’s disease published in
1984 provided a clear framework and an important
step forward for advancing clinical trials. Subse-
quently, severity levels of Alzheimer’s disease for the
purposeof clinical trialswereconventionallydefined
by reference to MMSE scores: mild to moderate, 10–
26; moderate to severe, ≤14; severe, less than 10 or
12; and mild disease, ≥20.
The evolution of inclusion criteria in clinical trials
reflects the change in clinical diagnosis towards
aetiologically directed diagnostic approaches as
compared to more clinically and phenotypically
based inclusion criteria. The extent to and speed
with which the proposed 2011 research diagnostic
criteria for Alzheimer’s disease [109] might replace
the 1984 criteria [12] for trials is not yet clear. The
essential difference between the two sets of criteria
is that biomarkers such as CSF Ab and tau
concentrations, cerebral glucose metabolism and
amyloid burden assessed by PET, and brain
volume biomarkers are integrated into the new
diagnostic criteria for probable and possible Alz-
heimer’s disease dementia [109]. This represents a
paradigm shift from conceptualizing Alzheimer’s
disease as being definitively diagnosable only
postmortem, with the diagnosis being predicted
with variable certainty in vivo (i.e. possible and
probable Alzheimer’s disease), to the construct of
Alzheimer’s disease as being reliably diagnosable
in life, even early in the course of illness, using
prognostic biomarkers.
Early on, trial inclusion criteria for MCI or amnes-
tic MCI followed either the Mayo clinic criteria [66]
or other criteria that generally required, in part, a
CDR global score of 0.5, and a New York Univer-
sity NYU paragraph recall score or Auditory Verbal
LearningTest AVLT score below a certain critical
level. The former MCI criteria were somewhat
more precisely defined, requiring memory impair-
ment using the Wechsler Memory Scale Logical
Memory II test at the same threshold limit as
required for Alzheimer’s disease dementia. All MCI
criteria as used in clinical trials further required
relative preservation of other aspects of cognitive
function and ADL. In retrospect, the Mayo clinic
criteria for amnestic MCI have been recognized as
being relatively stringent in their requirements for
memory impairment and led to identification of
subjects with relatively rapid rates of progression
to dementia. The criteria for ‘MCI due to Alzhei-
mer’s disease’ as used in one recent trial [66] are
the same as the new 2011 MCI due to Alzheimer’s
disease criteria except that the latter can be
further enriched with a range of Alzheimer-related
biomarkers [95]. By including one of the above-
mentioned biomarkers, the latter criteria become
essentially equivalent to the criteria for ‘prodromal
Alzheimer’s disease’ of an international workgroup
[97].
It remains unclear how the new definitions of
minor and major neurocognitive disorders in the
recently introduced 5th edition of the DSM will be
employed in Alzheimer’s disease drug develop-
ment. For example, the term ‘minor neurocogni-
tive disorder’ defines a population that overlaps
with MCI due to Alzheimer’s disease but also
allows for impairment in executive abilities with-
out memory deficits and is not aetiologically
based.
It is noteworthy that memory impairment thought
to be related to ageing, categorized by terms such
as age-associated memory impairment [110], age-
related cognitive decline and subjective memory
impairment or cognitive decline in the elderly, has
not been the focus of drug development. This may
reflect a lack of economic incentive, as from a
regulatory point of view such conditions are not
considered to be illnesses, which is a prerequisite
for approval of a drug. However, in the USA, food or
dietary supplements have been promoted for such
conditions. In this domain, disease treatment
claims are not made, but rather ‘structure/func-
tion claims’ (21 CFR 101.93) are advanced. The
emerging concept of preclinical Alzheimer’s dis-
ease, wherein there may or may not be evidence of
cognitive impairment but biological evidence of
Alzheimer’s disease pathology [97, 111] is present,
partially addresses the poorly defined space
between normal cognitive ageing and pathological
cognitive impairment.
In summary, diagnostic criteria for clinical trials of
Alzheimer’s disease have remained consistent for
more than a quarter of a century, and those for MCI
trials for more than a decade. The new research
criteria mainly incorporate biomarkers to increase
the likelihood of Alzheimer’s disease pathology in
patients clinically diagnosed as having prodromal
Alzheimer’s disease and MCI or to help define a
preclinical or presymptomatic Alzheimer’s disease
state.
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Outcomes in clinical trials
A narrow set of outcomes for Alzheimer’s disease
trials have been used since the mid-1980s. The
primary outcomes of the trials can be described
within cognitive, functional, global change and
severity domains (Table 5). The ADAS-cog [112],
ADCS-ADL scale [113], Disability Assessment for
Dementia (DAD) [114], Clinician Interview Based
Impression of Change with Caregiver Input
(CIBIC+) or ADCS Clinical Global Impression of
Change (ADCS-CGIC)) [115] and CDR [116] are
amongst the most commonly used. The two ADL
scales are often used interchangeably. The Pro-
gressive Deterioration Scale [117], however, is
noteworthy for its use as an ADL rating in impor-
tant regulatory trials for tacrine, galantamine and
rivastigmine. A Severe Impairment Battery [118] is
used as a primary outcome in moderate-to-severe
Alzheimer’s disease trials with memantine and
donepezil. The ADAS-cog was developed to assess
cognitive areas commonly impaired in patients and
is the standard cognitive outcome for the vast
majority of mild and mild to moderate and prodro-
mal or early Alzheimer’s disease trials. It includes
tests of memory, praxis, orientation, language,
reasoning and word-finding as well as, in extended
versions, executive function and attention.
The Neuropsychological Test Battery (NTB) was
introduced in early 2001 for a trial of the synthetic
Ab42 vaccine AN1792 [22]. It is an individualized
selection of neuropsychological tests mainly from
the Wechsler Memory Scale, the Rey Auditory
Verbal Learning Test and verbal fluency tests that
are combined into three batteries assessing imme-
diate and delayed memory and executive function
[119]. In theory, this composite score may be more
sensitive to change than the ADAS-cog for patients
with milder Alzheimer’s disease who retain episodic
memory capacity or the ability to learn. The NTB
has been used instead of or in addition to the
ADAS-cog in a few phase 2 and 3 trials. The ADAS-
cog, however, can be expanded to include tests of
executive function and episodic memory [112].
The ADCS-CGIC [115] for 3- to 18-month trials is
the most commonly used example of a global
change rating originally required by the FDA in
1990 [14]. The CDR is the most commonly used
severity rating in trials of 12 months and longer.
The former is used to assess clinically meaningful
change from baseline and the latter to assess
current severity of dementia, either on a staging
scale of 0–3 (0, 0.5, 1, 2, 3) or of 0–18 by adding the
scores for six cognitive and functional areas.
Since the first 6-month trials, co-primary outcomes
assessing cognition and either function or clinical
global change have been used in phase 2 and 3
trials that are intended as pivotal studies. For
regulatory purposes, the EMA and FDA have
required two primary outcomes, the ADAS-Cog
and either the ADCS-ADL or ADCS-CGIC.
Recently, the FDA suggested in their draft guidance
that the CDR-SB can be used as a ‘composite’ and
Table 5 Outcomes used in clinical trials for Alzheimer’s disease and mild cognitive impairment
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sole outcome in prodromal Alzheimer’s disease
trials and that a single neuropsychological assess-
ment can be used as sole outcome for preclinical
Alzheimer’s disease trials [98, 120]. The EMA has
also endorsed the use of the CDR-SB as sole
primary outcome as evidenced by ongoing 2-year
registration trials conducted in patients with pro-
dromal Alzheimer’s disease. However, a disease-
modifying claim will be granted by the EMA only
providing that there is a clinically relevant treat-
ment effect supported by additional CDR subitems
exploratory analyses and results from key second-
ary end-points as well as compelling evidence from
the biomarker programme showing delay in neu-
rodegeneration. The EMA requires a comprehen-
sive assessment of efficacy to support the primary
outcome that itself must be interpretable as clin-
ically meaningful in addition to being statistically
significant.
In summary, outcomes for phase 2 and 3 trials in
patients with mild-to-moderate Alzheimer’s disease
have been largely the same since 1988. Any vari-
ations have been in the use of a cognitive outcome
in addition to the ADAS-cog or the choice of ADL
rating, global change or severity scales. Recently,
the CDR-SB has been used as sole clinical outcome
in two prodromal Alzheimer’s disease trials and
sanctioned by the EMA and FDA, although sec-
ondary outcomes will be important in the interpre-
tation of any positive CDR-SB primary outcome.
The introduction of biomarkers in trials
The serial failures of drugs in 12- to 18-month
trials, especially the anti-Ab agents, led to a sug-
gestion that the primary reasons for failure were
that the patients selected for the trials with mild-
to-moderate disease were both too far advanced
into their illness and, simultaneously, some
patients did not have the neuropathology of Alz-
heimer’s disease. Therefore, according to this
reasoning, the drugs did not have enough oppor-
tunity to work as the brain contained too much
amyloid substrate, the neurodegeneration was too
advanced or the patients did not have the illness in
the first place. This rationale combined with the
wish to not just improve symptoms but to modify
the progression of Alzheimer’s disease pathology
encouraged focus on advancing potential biomar-
kers for diagnosis, sample enrichment, disease
progression and for targeting patients in an earlier
prodromal or mild dementia phase within a clinical
trials context.
The advancement of the amyloid hypothesis, as
well as advances in Ab and tau assay technology,
volumetric MRI and amyloid PET scans, led to the
use of putative CSF and imaging biomarkers in
clinical trials. The original purpose of CSF Ab and
tau assays in trials was as diagnostic and prog-
nostic markers of illness and later as potential
therapeutic, predictive, pharmacodynamic or sur-
rogate markers of the effects of a drug. Finally, the
EMA in 2011 and FDA in 2013 [98] recognized their
potential use as markers to enrich sample selection
in early-stage Alzheimer’s disease. The EMA qual-
ified both amyloid PET imaging and CSF Ab42 and
tau assays as enrichment biomarkers for enrolling
participants with either prodromal or mild-to-mod-
erate Alzheimer’s disease in regulatory clinical
trials [91, 92].
Most current longer-term trials use a biomarker in
a subset of participants, usually for exploratory
and sometimes for disease-modification pur-
poses. Thus far, biomarkers have been used in an
Ab-centric way. Biomarkers that are affected by the
drug might be used for enrichment and prediction,
but are limited for use as a surrogate clinical
outcome. For example, an Ab marker that is
affected by a test drug cannot be used as a
surrogate clinical outcome marker, but could be
used as a potential marker of pharmacodynamics.
It is useful to consider the types of biomarkers that
have been used in recent Alzheimer’s disease trials:
diagnostic – for determiningdiagnosis; enrichment –
for enhancing entry criteria; prognostic – for
determining the course of illness; predictive – for
determining treatment outcomes; and surrogate –
to substitute for clinical outcomes. However, for
the most part biomarkers still require validation for
the particular purpose for which they are used and
need more than just correlation with clinical
change.
The biomarkers used in clinical trials were devel-
oped with the intention of reflecting disease and
have been used extensively in observational stud-
ies. They were introduced into clinical trials as
potential prognostic and predictive markers. Bio-
marker outcomes in trials have been counterintu-
itive and are often difficult to interpret; the Ab
vaccine AN1792 was associated with decreased
brain volumes and decreases in amyloid plaques at
autopsy, whilst xaliproden was associated with
changes in MRI volumes and bapineuzumab with
decreases in CSF tau, but not Ab. These changes,
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however, occurred in the absence of detectable
clinical change. By comparison, another Ab anti-
body, solanezumab, was associated with no change
in biomarkers but the possibility of a clinical effect
in a subgroup with mild Alzheimer’s disease.
One explanation for counter-intuitive outcomes is
that analyses of biomarker subsets from individual
trials lack statistical power to detect significant
changes related to treatment effects. On the other
hand, the trials including biomarkers are not
designed to make a constructive comparison
between biomarker-positive and biomarker-nega-
tive patients. Such trials could potentially validate
biomarkers for diagnostic and labelling purposes,
and possibly as supportive evidence of clinical
outcomes, but would require either validation in a
biomarker-negative population or neuropathologi-
cal evidence. Another consideration is that biomar-
ker determinations and cut-off points are set
arbitrarily and vary across studies.
A method for validating a biomarker for a partic-
ular drug development programme is to document
the change in biomarker in phase 1, validate by
correlating with the clinical outcome in phase 2
and then use it in confirmatory phase 3 trials. The
given drug, however, would have to show efficacy at
the phase 2 proof of concept stage, which is
something that has not been accomplished in
Alzheimer’s disease trials for drugs other than
cholinesterase inhibitors [5].
An example of both qualification of a biomarker
and a companion biomarker is Takeda/Zinfandel
seeking both to qualify a compound biomarker
composed of a TOMM40 genotype, APOE genotype
and age, as a prognostic biomarker for risk of MCI
due to Alzheimer’s disease, and as a predictive
biomarker of the efficacy of very low-dose pioglit-
azone to delay onset of MCI due to Alzheimer’s
disease. This will involve a single phase 3 trial of
about 5800 participants without cognitive impair-
ment who will be followed for 5 years to investigate
the onset of ‘MCI due to Alzheimer’s disease’ or
Alzheimer’s disease dementia [121].
There is considerable hope that biomarkers can
first accurately measure biological change that
indicates disease progression and, secondly, be
validated as surrogate markers of clinical effect
and therefore, by virtue of being more precise than
the clinical measures, increase the statistical
power of clinical trials, thus requiring fewer par-
ticipants for faster and more efficient trials. In such
a scenario, the standard clinical outcomes (con-
sidered to be insensitive to change especially in
early illness) can be wholly replaced [94]. The
outcomes of the recent bapineuzumab and sola-
nezumab trials raised further questions regarding
the usefulness of current biomarkers as outcomes
for trials. Consideration regarding the use of bio-
markers should be given to several factors includ-
ing the type of therapeutic intervention, the clinical
stage of illness and the time dependence of bio-
marker changes during illness.
Although a risk factor and not a biomarker per se,
APOE genotype has been commonly treated as a
diagnostic or prognostic biomarker. Particular
development programmes and trials were designed
to predict or assess drug response based on
noncarriage of an APOE e4 allele, such as studies
with rosiglitazone and bapineuzumab and the
ongoing prevention trial with pioglitazone.
Regulatory considerations for drug development in Alzheimer’s
disease
The roles, responsibilities and actions of and guide-
lines developed by the regulatory authorities are
generally not well understood even by experts in the
field of drug development for Alzheimer’s disease.
Amongstmany other responsibilities, the FDA,EMA
and other agencies worldwide regulate and assure
the safety, effectiveness, quality, labelling andman-
ufacturing standards of prescription and nonpre-
scription drugs. Specifically they judge whether an
investigational drug intended for marketing is safe
and effective for its proposed use, the benefits of the
drug outweigh the risks, the proposed labelling (i.e.
package insert or prescribing information) is appro-
priate, and the manufacturing methods and con-
trols used to maintain quality are adequate in order
to approve the drug for marketing. In Europe,
Regulation (EC) No. 726/2004 states that drugs
for neurodegenerative disorders must be evaluated
centrally by the EMA rather than separately by each
individual member state.
As the science changes, regulatory positions evolve
as well, in general regulatory criteria for marketing
of therapies for Alzheimer’s disease require a
demonstration of cognitive efficacy and improve-
ments in function, that is, ADL, and/or evidence of
overall clinical improvement (according to FDA
draft guidelines [14, 120] and EMA formal guide-
lines [122]). Regulators have generally facilitated
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drug development by providing standards for later
phase development. For example, the FDA pro-
vided unofficial guidelines for trial methods for
demonstrating disease modification in 1996 [123]
and more recently proposed guidelines for prodro-
mal Alzheimer’s disease [98]. The EMA issued
detailed guidelines for disease modification [122]
and qualified novel methodologies, including the
use of biomarkers for enrichment.
However, guidelines may constrain some develop-
ment programmes by limiting how drugs with vastly
different actions used in a pleomorphic disorder can
be developed. Effectively, the guidelines encourage
very similar programmes regardless of the different
characteristics of the drugs or diagnostic subtlety.
Pharmaceutical companies and academics there-
fore may restrict themselves to planning standard
protocols that might not be themost appropriate for
the drug under development.
For these reasons, regulatory agencies may be
involved very early in drug development pro-
grammes encouraging companies to seek scientific
advice meetings (Fig. 3). The EMA, for instance, has
established the Scientific Advice Working Party
(SAWP) which consists of experts in areas includ-
ing nonclinical quality and biostatistics, and con-
nects with a network of external clinical experts
and patient representatives from the EU. These
processes serve to bring together the major stake-
holders to develop common protocols for develop-
ing new therapeutics for Alzheimer’s disease.
Recent development programmes have tended to
place greater emphasis on patients with mild or
early Alzheimer’s disease, but it might be expected
that efficacy of a treatment that delays disease
progression would be demonstrated in trials at
different stages of illness. Phase 3 trials for symp-
tomatic drugs commonly have a duration of 6 or
12 months, compared with 18 and 24 months for
drugs that could be considered as disease modify-
ing in mild/mild to moderate and in prodromal
Alzheimer’s disease, respectively; however, study
length does not determine the intention for a
disease-modifying trial.
According to the EMA, cholinesterase inhibitors are
considered standard care (despite their controver-
sial health effectiveness status) such that a drug
being developed needs to be assessed also in a
phase 3 add-on design wherein the new drug is
used in a placebo-controlled trial in patients
already maintained on cholinesterase inhibitors.
However, this occurs de facto as it is very difficult
to recruit to long-term clinical trials patients with
Alzheimer’s disease who are not taking these
drugs.
Disease-modification claims
The quest for a disease-modifying marketing claim
to be endorsed by the EMA or FDA is driven by the
pharmaceutical industry’s assessment that it
would sell more drug and at a higher price with



































Fig. 3 The drug development process from preclinical development to approval. The focus of this review is phase 2 to phase
3 development. In general, the trials discussed were planned as phase 2, 2a or 3. Some phase 2 trials discussed were
pivotal and could have been the basis for regulatory approval if the results had been positive. Modified from the FDA
publication, Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products.
http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm.
BLA, biologics licence application; FDA, Food and Drug Administration; IND, Investigational new drug application; NDA,
New drug application.
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cians would welcome a drug that worked over a
long period whether or not it is called a disease
modifier. In the late 1990s, the FDA informally
suggested two methods to demonstrate disease
modification that would be sufficient for a health
claim: a randomized-start and a randomized-with-
drawal design [123].
Until recently, only the EMA offered guidelines that
suggested a method for disease modification.
According to the EMA, biomarkers should correlate
with the presumedmechanism of action of the drug
and ultimately, it is hoped, with the clinical efficacy
of the drug [91]. So far, however, no such relation-
ship has been observed other than in small subsets
of larger trials that showed null results in terms of
the primary outcomes for the drug in question. For
example, an Ab vaccine, AN1792, may reduce CSF
phosphorylated-tau (P-tau) protein [22] and amy-
loid plaque density on autopsy but with no appar-
ent clinically advantageous effects [124]. A trial of
bapineuzumab including only 29 patients showed
a small decrease in fibrillar Ab on PiB-PET imaging
and a decrease in CSF P-tau after 18 months of
treatment [125, 126]. There was a potential trend,
depending on the statistical analysis, for tramipro-
sate to be associated with increased hippocampal
volume in a subgroup [127]. In phase 3 bap-
ineuzumab trials, relative decreases in PiB-PET
uptake and CSF P-tau were observed in subsets of
patients [Janssen CTAD presentation, 2012]. All
these observations, however, were unrelated to
clinical improvement (which did not occur) with
the experimental drugs and do not provide evi-
dence to support the biomarkers in question.
In early 2013, the FDA produced guidelines for a
disease-modification marketing claim in the con-
text of early-stage Alzheimer’s disease that are
more compatible with the those of the EMA [98,
120]. By early stage, the FDA means ‘symptomatic’,
preclinical Alzheimer’s disease (so-called stage 3
preclinical) and MCI due to Alzheimer’s disease
which it considers to be the same as prodromal
disease. These draft guidelines allow for the possi-
bility ‘that a claim of disease modification could be
supported by evidence of a meaningful effect on a
biomarker in combination with a clinical benefit’,
or through the use of a randomized-start design
trial in which patients who were initially receiving
placebo and then assigned to active treatment
would be expected to fail to catch up in order for
the drug to receive a disease-modification claim.
The FDA prefers the latter option and first pro-
posed this clinical trial design two decades earlier
[123]. It was noted, however, that for the former to
be the case, ‘there should be widespread evidence-
based agreement in the research community that
the chosen biomarker reflects a pathophysiologic
entity that is fundamental to the underlying dis-
ease process. There is currently no consensus as to
what particular biomarkers would be appropriate
to support clinical findings in trials in early AD
[Alzheimer’s disease]’.
Figure 4 shows a schematic example of a random-
ized-start design, demonstrating the type of clinical
effect that could be considered disease modifying.
Indeed, in the late 1990s, a 12-month trial of
propentofylline built in both a randomized-start
and randomized-withdrawal design by re-random-
izing at 12 months and in a double-blind manner
extending the trial by 6 months [54]. However, the
drug was withdrawn from development.
In evaluating the development plans of mainly
anti-amyloid drugs, the EMA has issued further
scientific advice as to how to contextualize a
disease-modification claim in the light of the quest
to treat patients with very-early-stage disease and
to develop diagnostic companion biomarkers.
Assuming that prodromal Alzheimer’s disease and
dementia are part of a continuum, the efficacy of a



















Fig. 4 Illustration of a randomized-start design for a
regulatory clinical trial to demonstrate disease modifica-
tion. Reproduced with permission from Leber [121].
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be demonstrated in two trials. The first trial should
recruit patients with early-stage disease with vir-
tually no functional impairment at baseline, and
efficacy should be demonstrated on a composite
end-point, such as the CDR-SB, or possibly a
single primary end-point providing that it is vali-
dated in this population. The second trial should
recruit patients with mild or mild-to-moderate
disease, with efficacy demonstrated on two
co-primary end-points addressing both cognition
and function. The evidence from both trials should
be robust and supported by secondary end-points
including responder analyses and biomarkers that
show delay in brain neurodegeneration.
The FDA has emphasized that a disease modifica-
tion claim would be seen as an extraordinary major
claim, implying that nearly all individuals at risk of
Alzheimer’s disease would need to take the drug,
putting the prospects for approval of a drug with a
disease-modification claim in a realistic context.
One challenge for disease-modifying drugs will be
their costs especially if the majority of older people
use them. Cost-effectiveness estimates in this area
are controversial, although the findings of a Swed-
ish simulation study suggested that the main costs
were the price of the drug and the cost of an
expected 1-year decrease in mortality. An optimis-
tic, incremental cost-effectiveness ratio was esti-
mated at $50 000 per Quality-Adjusted Life Year,
with no cost savings, but below an expected
willingness-to-pay range, at least in Sweden
[128]. However, long-term data are needed to
understand the progression of change beyond the
trial period, and particularly with drugs intended
to interfere with the amyloid cascade to assess for
any worsening or rebound that may occur with
prolonged therapy.
Discussion
The only drugs approved for the treatment of
Alzheimer’s disease over the past 30 years have
been cholinesterase inhibitors and memantine,
and none has been approved since 2003. Nearly
200 drugs were advanced to at least the level of
phase 2 development. Moreover, the approved
drugs show limited clinical effect, and there is
controversy regarding whether they are therapeu-
tically useful (Fig. 5. The most probable explana-
tion for this failure, of course, is that the tested
drugs simply were not effective for their intended
indication. Alzheimer’s disease is a complex, mul-
tidetermined disease with a pleomorphic pheno-
type. There are many potential drug targets and so
far no validated targets except perhaps for the
cholinergic system.
Although very few of the many negative trials give
clear information about why results were null or
inconclusive, the methods used to develop the
drugs should be viewed with caution and critically
appraised. Important issues include whether
development programmes and trial methods have
gone wrong, and are there better approaches to
late-stage trials that might enhance the likelihood
of success?
Explaining after the fact why trials failed despite
our best efforts is speculative and any rationaliza-
tions are likely to be incorrect. One current expla-
nation is that patients should have been treated
earlier, particularly those with milder illness
and who have amyloid markers associated with
Alzheimer’s disease pathology. However, although
rational and based on observations that amyloid
biomarkers in some cohorts precede symptoms,
there is no supporting evidence that this approach
will be effective. Many phase 2 and 3 trials now
include a diagnosis of prodromal Alzheimer’s dis-
ease supported by amyloid PET scans or CSF Ab
Fig. 5 A comparison of the same effects of donepezil with
standard deviation bars showing the distribution of drug
and placebo outcomes and standard error bars indicating
the precision of the outcomes measures. Reproduced with
permission from Lindner et al. [2].
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despite the limited evidence about biomarkers
validity.
The only consistency in drug development for Alz-
heimer’s disease that might constitute a successful
approach is for drugs that affect the cholinergic
system. The cholinesterase inhibitors, including
those that were not marketed, showed consistent,
albeit small, statistical efficacy over 6 and some-
times 12 months. Even so the drugs do not achieve
the minimum clinically important drug–placebo
difference of 4 points on the ADAS-cog that was
sought by experts in the 1990s; in addition, they are
not effective in MCI, that is, in patients who are
likely to have amyloid pathology and progress to
Alzheimer’s disease. Thus, a ‘treat-early’ hypothesis
is unlikely to be sustained with cholinesterase
inhibitors. A model of clinical trials that was
recently qualified by the FDA and EMA [129] dem-
onstrated that cholinesterase inhibitors do not
change illness course and have negligible long-term
effects on the ADAS-cog.
Muscarinic M1 agonists showed slight but overall
consistent effects. Furthermore, other drugs in
development that affect the cholinergic system
includinga7allostericmodulators and5-HT6antag-
onists have shown measurable cognitive effects
across compounds and are in active development.
Moreover, the phase 2 and 3 trials showed efficacy
with from 400 to 700 patients, far fewer than the
sizes of phase 2 and 3 trials for the anti-amyloid
drugs that did not show significant effects. In
retrospect, this level of consistency demonstrates a
robust proof of concept for the cholinergic hypoth-
esis despite the small magnitude of the clinical
effects. It is notable that there have been no formal a
priori attempts to maximize the effects of cholines-
terase inhibitors, for example, to identify and target
clinical subgroups that might be better responders.
By comparison, the results of trials of drugs for
other targets have been disappointing. For exam-
ple, although well-reasoned and based on preclin-
ical studies, anti-inflammatory agents, conjugated
oestrogens, secretase inhibitors and Ab vaccines
have had unexpected ‘opposite’ (i.e. cognition-
impairing) effects and failed in trials intended
to be confirmatory. Phase 3 trials should be
hypothesis confirming and such surprises should
not be common.
A milestone for drug development is the progres-
sion from phase 2, a safety and proof of concept
phase, to pivotal trials in phase 2b or 3. The regular
failures in phase 3 suggest that decisions may not
be based on the evidence from phase 2, that phase
2 is not informative or that we may be acting on
signals that are not signals; in particular, over-
valuing or misinterpreting post hoc subset analy-
ses. For example, the phase 2 trials of tarenflurbil
and bapineuzumab did not show significant out-
comes, phase 2 safety findings for semagacestat
demonstrated major toxicity, and phase 2 was
avoided for solanezumab except to establish min-
imal safety for phase 3 and pharmacodynamic
changes in Ab. Under these circumstances, the
negative outcomes of the subsequent phase 3 trials
should not have been surprising.
No anti-amyloid therapy phase 3 trial has been
preceded by a positive phase 2 proof of concept
trial. Moreover, the fact that the protocols of
some pivotal trials had to be changed during the
study because of toxicity means that character-
istics of the drugs, dosages and targets were not
known before entering confirmatory trials. In
summary, an unfortunate characteristic of devel-
opment programmes for Alzheimer’s disease has
been that phase 2 does not provide ‘proof of
concept’ to predict phase 3, but rather is used as
a bridge to the next stage. Thus, the large phase
3 trials, instead of being confirmatory, are often
exploratory.
The decision to advance a drug may be more
dependent on how pharmaceutical companies
make decisions than on an evidence-based likeli-
hood of efficacy. A phase 3 trial may be undertaken
without phase 2 support based on business con-
siderations about the future sales and profits over
the duration of the drug’s marketing life. Therefore,
the sponsor may be willing to spend relatively large
amounts on late-stage trials whilst recognizing the
high probability of failure in pursuit of extremely
large returns over the life of the drug. As the phase
2 trials are negative, the phase 3 trials are con-
ducted without adequate prior information for
planning, often with data gleaned from post hoc
subgroup analyses, and methods duplicated from
previous, unsuccessful trials. The new trial
represents, in effect, a large call option for the
pharmaceutical company.
Although many drugs should not have been
brought into phase 2 or 3, for many more develop-
ment was in fact stopped early and appropriately in
phase 1 and 2a, and these trials were not included
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is this review focused on late-stage development.
Some drugs in phase 3 programmes do have
significant efficacy results from phase 2 trials to
support their advancement. These drugs are
mainly small molecules, so-called symptomatic
often cholinergically acting compounds, and not
considered disease-modifying agents.
Another characteristic of the methods used for
trials in Alzheimer’s disease is that drugs with very
different therapeutic activities and outcome expec-
tations are developed using essentially the same
phase 2 and phase 3 clinical trial designs as were
used with cholinesterase inhibitors in the early
1990s [5,100]. There are few adaptations in trial
design for the unique characteristics of different
drugs, durations of use, mechanisms by which
they exert their effects or any expected different
outcomes. Late-phase development does not seem
to be tailored to a drug’s unique characteristics or
to the patients who might benefit.
The minimal changes in trial methods may be a
consequence of having no successes to build on and
the perceived risk aversion of companies and aca-
demics to making changes. Thus, small changes
occur: MMSE criteria ranges are expanded or con-
tracted, trial durations are lengthened, similar out-
comes are exchanged, sample sizes are increased,
amyloid biomarkers are used to increase diagnostic
confidence, and smaller clinical effects are sought.
Notably, trialsnowrequire drug–placebodifferences
of only 1–2 points on the ADAS-cog over 18–
24 months, that is, half the effect in three times
thedurationof treatment thanhadbeensoughtwith
the cholinesterase inhibitors (Fig. 5).
More refined diagnostic and prognostic markers
have advantages and disadvantages. The use of
biomarkers may lead to sample enrichment of
patients who might benefit from a particular
drug, future identification of valid subtypes and
drug-responsive genotypes and phenotypes. On
the other hand, the current markers being
advanced may be pseudo-specific to the illness
and its progression or may indicate more advanced
illness.
In this nonsystematic review, important drugs may
havemissed andothersmayhavebeen over-empha-
sized. Yet it is apparent that phase 2 and 3 drug
development has been over-represented by anti-
amyloid approaches. It is beyond the scope of this
review to comment on the validity of the amyloid
cascade hypothesis. It is not possible to extrapolate
fromtrial failures to refute thehypothesis; todoso, it
must be known or demonstrated that the drug
entered the brain, had a clear effect on the target
and then resulted in no effect. Without such infor-
mation, it can only be concluded that these
approaches have been tested inadequately.
Conclusions and future directions
The sustainability of and methods of conducting
large clinical development programmes in Alzhei-
mer’s disease are questionable. Many trials are
including earlier-stage diagnoses or at-risk states,
requiring greater numbers of participants, and
longer follow-up periods now extending beyond
18 months. The prevention trials are longer still,
possibly including a majority of participants who
may not develop clinical Alzheimer’s disease during
the follow-up period or their lives. Specifically,
phase 2 and 3 development programmes have
grown from trials with 400–700 participants and
two 6-month trials, to 1200–2300 participants in
trials extending to 24 months.
There is a need to better appreciate the pleomor-
phism of the illness, its competing risk factors and
precipitants such as age, genetics, environmental
factors and cerebrovascular and cardiovascular
disease. The wide range of targets make it unlikely
that affecting one alone will lead to a more than
minimally effective therapeutic agent.
The goal of enrichment with biomarkers is targeted
research. However, targeted clinical trials also
need to be focused, based on the drug, patient
characteristics and ideally a companion biomar-
ker. Better, smarter phase 2 studies are needed to
identify potentially effective drugs for phase 3. This
could involve fewer patients, drug-specific out-
comes and protocol designs that can be changed
or adapted after randomization. Phase 3 trials may
need to be more efficiently designed with clinically
relevant and more precise outcomes.
Past failures and the dichotomies of symptomatic
versus disease-modifying, early versus late and
amyloid versus not suggest that there is still much
to learn about late-phase development. Less
emphasis should be placed on consensus, received
wisdom, precedence and wishfulness and more on
prior knowledge, as consensus does not mean that
what is done is correct. The lack of progress despite
substantial effort may rest, as stated by Leber, a
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former FDA director, ‘Not in our methods, but in
our ignorance’ [130].
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